TIDMDNL TIDMTTM

RNS Number : 3056Y

Diurnal Group PLC

05 September 2022

FORM 8 (OPD)

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

   1.         KEY INFORMATION 
 
 (a) Full name of discloser:                                                                    Diurnal Group PLC 
 (b) Owner or controller of interests and short positions disclosed, if different from 1(a):    N/A 
  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), 
  settlor and beneficiaries must be named. 
                                                                                               ------------------ 
 (c) Name of offeror/offeree in relation to whose relevant securities this form relates:        Diurnal Group PLC 
  Use a separate form for each offeror/offeree 
                                                                                               ------------------ 
 (d) Is the discloser the offeror or the offeree?                                               OFFEREE 
                                                                                               ------------------ 
 (e) Date position held:                                                                        2 September 2022 
  The latest practicable date prior to the disclosure 
                                                                                               ------------------ 
 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect   N/A 
  of any other party to the offer? 
  If it is a cash offer or possible cash offer, state "N/A" 
                                                                                               ------------------ 
 
   2.         POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 
 Class of relevant security:                                                    Ordinary shares of GBP0.05 each 
                                                                                Interests            Short positions 
                                                                               -------------------  ------------------ 
                                                                                Number       %       Number       % 
                                                                               -----------  ------  -----------  ----- 
 (1) Relevant securities owned and/or controlled:                               Nil          Nil     Nil          Nil 
                                                                               -----------  ------  -----------  ----- 
 (2) Cash-settled derivatives:                                                  Nil          Nil     Nil          Nil 
                                                                               -----------  ------  -----------  ----- 
 (3) Stock-settled derivatives (including options) and agreements to            Nil          Nil     Nil          Nil 
 purchase/sell: 
                                                                               -----------  ------  -----------  ----- 
                                                                                Nil          Nil     Nil          Nil 
   TOTAL: 
                                                                               -----------  ------  -----------  ----- 
 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

   (b)        Rights to subscribe for new securities 
 
 Class of relevant security in relation to which subscription right exists:    N/A 
 Details, including nature of the rights concerned and relevant percentages:   N/A 
                                                                              ---- 
 
   3.         POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE 
 
 Details of any interests, short positions and rights to subscribe (including directors' and 
  other employee options) of any person acting in concert with the party to the offer making 
  the disclosure: 
 
         a) Ordinary Shares held by directors of Diurnal Group PLC 
                                                     % of Issued 
                             Number of Ordinary    Share Capital 
                                         Shares    (170,040,825) 
          Richard Ross                2,284,047            1.34% 
                            -------------------  --------------- 
          Richard Bungay                337,578            0.19% 
                            -------------------  --------------- 
          John Goddard                  228,574            0.13% 
                            -------------------  --------------- 
          Samuel Williams               113,819            0.06% 
                            -------------------  --------------- 
          Alan Raymond                   66,849            0.03% 
                            -------------------  --------------- 
 
 
         b) Options and awards held by directors of Diurnal Group PLC 
 
         Long Term Incentive Plan: 
                                 Maximum      Date of   Exercise       Vesting      Exercise 
                               number of        Grant      Price          date        Period 
                            share awards 
          Richard Ross            71,743   04/12/2018        Nil        Vested        Expiry 
                                                                                  04/12/2028 
                          --------------  -----------  ---------  ------------  ------------ 
          Richard Ross            82,431   10/01/2020        Nil       Vesting        Expiry 
                                                                    10/01/2023    10/01/2025 
                          --------------  -----------  ---------  ------------  ------------ 
          Richard Ross           137,860   18/12/2020        Nil       Vesting        Expiry 
                                                                    18/12/2023    18/12/2025 
                          --------------  -----------  ---------  ------------  ------------ 
          Richard Ross           155,899   14/12/2021        Nil       Vesting        Expiry 
                                                                    31/12/2024    31/12/2026 
                          --------------  -----------  ---------  ------------  ------------ 
          Richard Bungay         242,857   08/05/2017    GBP0.05        Vested        Expiry 
                                                                                  18/05/2027 
                          --------------  -----------  ---------  ------------  ------------ 
          Richard Bungay          56,877   17/10/2017    GBP0.05        Vested        Expiry 
                                                                                  17/10/2027 
                          --------------  -----------  ---------  ------------  ------------ 
          Richard Bungay         204,083   04/12/2018        Nil        Vested        Expiry 
                                                                                  04/12/2028 
                          --------------  -----------  ---------  ------------  ------------ 
          Richard Bungay         239,172   10/01/2020        Nil       Vesting        Expiry 
                                                                    10/01/2023    10/01/2025 
                          --------------  -----------  ---------  ------------  ------------ 
          Richard Bungay         411,764   18/12/2020        Nil       Vesting        Expiry 
                                                                    18/12/2023    18/12/2025 
                          --------------  -----------  ---------  ------------  ------------ 
          Richard Bungay         374,434   14/12/2021        Nil       Vesting        Expiry 
                                                                    31/12/2024    31/12/2026 
                          --------------  -----------  ---------  ------------  ------------ 
 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

   4.         OTHER INFORMATION 
   (a)        Indemnity and other dealing arrangements 
 
 Details of any indemnity or option arrangement, or any agreement or understanding, formal 
  or informal, relating to relevant securities which may be an inducement to deal or refrain 
  from dealing entered into by the party to the offer making the disclosure or any person acting 
  in concert with it: 
  Irrevocable commitments and letters of intent should not be included. If there are no such 
  agreements, arrangements or understandings, state "none" 
 
   None 
 
   (b)        Agreements, arrangements or understandings relating to options or derivatives 
 
 Details of any agreement, arrangement or understanding, formal or informal, between the party 
  to the offer making the disclosure, or any person acting in concert with it, and any other 
  person relating to: 
  (i) the voting rights of any relevant securities under any option; or 
  (ii) the voting rights or future acquisition or disposal of any relevant securities to which 
  any derivative is referenced: 
  If there are no such agreements, arrangements or understandings, state "none" 
 
   None 
 
   (c)        Attachments 

Are any Supplemental Forms attached?

 
 Supplemental Form 8 (Open Positions)   NO 
 Supplemental Form 8 (SBL)              NO 
                                       --- 
 
 
 Date of disclosure:    2 September 2022 
 Contact name:          Mike Scott 
                       -------------------- 
 Telephone number:      +44 (0)20 3727 1000 
                       -------------------- 
 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FEELELFBLKLXBBE

(END) Dow Jones Newswires

September 05, 2022 08:36 ET (12:36 GMT)

Neurocrine Biosciences (LSE:0K6R)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Neurocrine Biosciences.
Neurocrine Biosciences (LSE:0K6R)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Neurocrine Biosciences.